Looking for Sense in the Italian Antitrust Authority Decision in the Pfizer Xalatan Case

Daniela Ampollini, Jul 27, 2012

The January 2012 decision of the Italian Antitrust Authority (“IAA”) in the Pfizer case, involving Pfizer’s actions to counter the marketing of generic versions of its product Xalatan, has given rise to a debate which has hardly appeased. Many commentators have already provided their impression from a competition law perspective. I, a patent lawyer, will try to provide mine, starting from the meaning and function of the patent law categories involved.

This content is for paid subscriptions only. Click Here to Subscribe

RECOMMENDED FOR YOU
 


More Articles